MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaad.2024.03.008

Медицинская библиотека · Journal of the American Academy of Dermatology · 2024

Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis.

James Warren A, Rosenberg Angela L, Wu Jashin J, Hsu Sylvia, Armstrong April, Wallace Elizabeth B, Lee Lara Wine, Merola Joseph, Schwartzman Sergio, Gladman Dafna, Liu Clive, Koo John, Hawkes Jason E, Reddy Soumya, Prussick Ron, Yamauchi Paul, Lewitt Michael, Soung Jennifer, Weinberg Jeffery, Lebwohl Mark, Glick Brad, Kircik Leon, Desai Seemal, Feldman Steven R, Zaino Mallory L

СтатьяОбзорКлинические рекомендацииПеревод в очереди

Аннотация

BACKGROUND

Systemic immunomodulatory agents are indicated in the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. Perioperative use of these medications may increase the risk of surgical site infection (SSI) and complication.

OBJECTIVE

To evaluate the risk of SSI and complication in patients with chronic autoimmune inflammatory disease receiving immunomodulatory agents (tumor necrosis factor-alfa [TNF-α] inhibitors, interleukin [IL] 12/23 inhibitor, IL-17 inhibitors, IL-23 inhibitors, cytotoxic T-lymphocyte-associated antigen-4 costimulator, phosphodiesterase-4 inhibitor, Janus kinase inhibitors, tyrosine kinase 2 inhibitor, cyclosporine (CsA), and methotrexate [MTX]) undergoing surgery.

METHODS

We performed a search of the MEDLINE PubMed database of patients with chronic autoimmune inflammatory disease on immune therapy undergoing surgery.

RESULTS

We examined 48 new or previously unreviewed studies; the majority were retrospective studies in patients with rheumatoid arthritis and inflammatory bowel disease.

CONCLUSION

For low-risk procedures, TNF-α inhibitors, IL-17 inhibitors, IL-23 inhibitors, ustekinumab, abatacept, MTX, CsA, and apremilast can safely be continued. For intermediate- and high-risk surgery, MTX, CsA, apremilast, abatacept, IL-17 inhibitors, IL-23 inhibitors, and ustekinumab are likely safe to continue; however, a case-by-case approach is advised. Acitretin can be continued for any surgery. There is insufficient evidence to make firm recommendations on tofacitinib, upadacitinib, and deucravacitinib.

Для цитирования: James Warren A, Rosenberg Angela L, Wu Jashin J, Hsu Sylvia, Armstrong April, Wallace Elizabeth B, Lee Lara Wine, Merola Joseph, Schwartzman Sergio, Gladman Dafna, Liu Clive, Koo John, Hawkes Jason E, Reddy Soumya, Prussick Ron, Yamauchi Paul, Lewitt Michael, Soung Jennifer, Weinberg Jeffery, Lebwohl Mark, Glick Brad, Kircik Leon, Desai Seemal, Feldman Steven R, Zaino Mallory L. Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis and psoriatic arthritis.. Journal of the American Academy of Dermatology. 2024. DOI: 10.1016/j.jaad.2024.03.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.